Pyoderma gangrenosum Archives - Willingsford Healthcare

About
How to Use
- How to use Amicapsil
- How to use SertaSil
Technology
- MPPT – micropore particle technology
SCI
Wounds
- Amicapsil – Humans
- SertaSil – Animals
Dermatology
- Aprobaxil – Humans
- Adinasil – Animals
Sustainability
- Sustainability
- Antimicrobials and Climate Change
Info
Shop

About
How to Use
- How to use Amicapsil
- How to use SertaSil
Technology
- MPPT – micropore particle technology
SCI
Wounds
- Amicapsil – Humans
- SertaSil – Animals
Dermatology
- Aprobaxil – Humans
- Adinasil – Animals
Sustainability
- Sustainability
- Antimicrobials and Climate Change
Info
Shop

Two clinical studies confirm Amicapsil’s effect on pressure injuries

Two clinical studies confirm
Amicapsil’s effect on pressure injuries

Download Publication

Both studies find 100% closure rates
for acute and chronic pressure injuries

Slider-web-AMR

See video, where Lady-Marie from UK Spinal Injuries Association describes how Amicapsil has treated her pressure injuries

Slider-web-60%

MPPT removes wound infections 60%
quicker than antibiotics and antiseptics.

Effective on resistant infections and does not contribute to AMR.

Slider-web-passive-immunotherapy

Passive Immunotherapy

acting via the skin and wound microbiome without the use of antimicrobials.

Slider-web-pain-etc

Amicapsil and Amicapsil-SCI

Effective wound treatment in immunocompetent and immunocompromised persons

Effective on antibiotic and antiseptic resistant wound infections.
Effective in immunocompetent and immunocompromised persons.

Slider-web-1

Less Scarring

“Where I have used Acapsil the scarring is flat, whereas the older scars are hypertrophic.” Patient ST

“Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic.” Patient ST

“Where I have used Aprobaxil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic.” Patient ST

Slider-web-1 – NH

“Amicapsil changed my life.”

“From 4 weeks of absolute hell – to being pain-free, getting a full night’s sleep and back to normal at work.”

“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”

NH ( patient)

Slider-web-15

69.5% Savings

Cost-effectiveness determined in NHS Clinical Audit

Slider-web-hypoallergenic

Hypoallergenic

Only natural ingredients

Slider-web-FDA

FDA concluded in 2022:

Standard wound products, including antimicrobials, are ineffective.

US FDA 2016

Verma et al. (2022)

Slider-web-AMR

Amicapsil-SCI

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.

Slider-web-AMR

Antibiotics reduce the amount of carbon that can be stored in soil. This directly increases CO2 in the atmosphere and contributes to climate change.
One course of antibiotic release the same amount of carbon as a car driving around Earth 1.47 times.

Slider-web-No-brainer

“For me, this Amicapsil open air method is a no brainer. It is easier, no fuss, and obviously cheaper than these expensive dressings.”

VH (patient)

Slider-web-Pollution

MPPT is environmentally sustainable:
it is biologically recyclable and does not require the use of chemicals, plastics or antimicrobials.

Clinical evaluation in pyoderma gangrenosum

Pyoderma gangrenosum (PG) is a rare neutrophilic inflammatory condition. It is characterised by painful, rapidly expanding, violaceous, undermined ulcers. Immunosuppressants are key to management, but

Willingsford Limited

NFEC, Rushington Business Park

Chapel Lane, Totton

Southampton SO40 9LA, United Kingdom

Phone: +44(0)23 8081 2325

E-mail: contact @ willingsford.com

Clinical evaluation in pyoderma gangrenosum

Willingsford Limited

News

June 20’th, 2024 – Patient survey of MPPT published in Frontiers in Rehabilitation Sciences

January 5’th, 2024 – MPPT clinical study published in Frontiers in Medicine

October 8’th to 11’th, 2023 – Spinal Injuries Association presents poster on Amicapsil at the annual ISCoS meeting.

August 19, 2023 – Petition to make Amicapsil-SCI available on prescription.